Back to search
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Clinicaltrials.gov:
EU CTIS:
#2025-521976-80-00
Other:
#79635322MMY2001
Interested in this trial?
Subscribe or share this trial
Trials at a glance
Status
Enrolling
Condition
Multiple Myeloma
Trial type
Interventional
Trial phase
Phase 2
Investigational
product
product
JNJ-79635322
Age
18+ years old
Biological sex
All
Placebo?
No
Trial start date
February 8, 2026
Trial end date
December 12, 2028
CT.gov ID
#NCT07266441
Share the trial ID with your doctor to see if trial participation is right for you. Participation depends on an independent medical assessment.
Countries:
- Israel,
- Japan,
- Poland,
- South Korea,
- Turkey (Türkiye),
- United States
Loading...
Enrolling
Seoul, South Korea, 05505
Enrolling
Gilbert, Arizona, United States, 85234
Enrolling
O'Fallon, Illinois, United States, 62269
Enrolling
Jacksonville, Florida, United States, 32256
Enrolling
Los Alamitos, California, United States, 90720
Enrolling
Jeollanam-do, South Korea, 58128
Enrolling
Duarte, California, United States, 91010
Enrolling
Irvine, California, United States, 92618
Enrolling
Cleveland, Ohio, United States, 44195
Enrolling
Denver, Colorado, United States, 80218
Enrolling
Atlanta, Georgia, United States, 30322
Enrolling
Afula, Israel, 1834111
Enrolling
Jerusalem, Israel, 9112000
Enrolling
Hadera, Israel, 3820302
Enrolling
Ankara, Turkey (Türkiye), 06680
Enrolling
Houston, Texas, United States, 77030
Enrolling
Boston, Massachusetts, United States, 02114
Enrolling
Antalya, Turkey (Türkiye), 07025
Enrolling
New York, New York, United States, 10065
Enrolling
Waukee, Iowa, United States, 50263
Enrolling
Okayama, Japan, 701-1192
Enrolling
Gunma, Japan, 377-0280
Enrolling
Tacoma, Washington, United States, 98405
Enrolling
Atlanta, Georgia, United States, 30342
Enrolling
Birmingham, Alabama, United States, 35294
Enrolling
Eugene, Oregon, United States, 97401
Enrolling
Houston, Texas, United States, 77030
Enrolling
Petah Tikva, Israel, 4941492
Enrolling
Aurora, Colorado, United States, 80012
Enrolling
New Brunswick, New Jersey, United States, 08901
Enrolling
Nashville, Tennessee, United States, 37203
Enrolling
Krakow, Poland, 30 688
Enrolling
Ashdod, Israel, 7747629
Enrolling
Seoul, South Korea, 06351
Enrolling
Seoul, South Korea, 03080
Enrolling
Seoul, South Korea, 03722
Enrolling
Kielce, Poland, 25 734
Enrolling
Brzozów, Poland, 36 200
Enrolling
Tel Aviv, Israel, 6423906
Enrolling
Nashville, Tennessee, United States, 37203
Enrolling
Austin, Texas, United States, 78705
Enrolling
Tyler, Texas, United States, 75702
Enrolling
Seoul, South Korea, 06591
Enrolling
San Francisco, California, United States, 94143
Enrolling
Iowa City, Iowa, United States, 52242
Enrolling
Philadelphia, Pennsylvania, United States, 19104
Enrolling
Wroclaw, Poland, 50 367
Enrolling
Poznan, Poland, 60-569
Enrolling
Fairfax, Virginia, United States, 22031
Enrolling
Norfolk, Virginia, United States, 23502
Enrolling
Lodz, Poland, 93 513
#
More than 50 sites in this region
#
More than 10 sites in this region
#
Less than 10 sites in this region
Individual sites
Access detailed information on the trial:
Clinical trials information
© Johnson & Johnson and its affiliates 2026
